Form 8-K - Current report:
SEC Accession No. 0001193125-23-233693
Filing Date
2023-09-13
Accepted
2023-09-12 21:17:59
Documents
12
Period of Report
2023-09-11
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Document Format Files

Seq Description Document Type Size
1 8-K d387807d8k.htm   iXBRL 8-K 27609
  Complete submission text file 0001193125-23-233693.txt   151531

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA fdmt-20230911.xsd EX-101.SCH 2898
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE fdmt-20230911_lab.xml EX-101.LAB 17978
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE fdmt-20230911_pre.xml EX-101.PRE 11290
6 EXTRACTED XBRL INSTANCE DOCUMENT d387807d8k_htm.xml XML 3360
Mailing Address 5858 HORTON STREET #455 EMERYVILLE CA 94608
Business Address 5858 HORTON STREET #455 EMERYVILLE CA 94608 5105052680
4D Molecular Therapeutics, Inc. (Filer) CIK: 0001650648 (see all company filings)

EIN.: 473506994 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39782 | Film No.: 231251459
SIC: 2836 Biological Products, (No Diagnostic Substances)